New Drug Nulibry Approved to Fight Deadly Rare Disease
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light to fosdenopterin (Nulibry), a breakthrough treatment for Molybdenum Cofactor Deficiency (MoCD) Type A. This rare genetic disorder can cause severe brain damage in newborns.
What is MoCD Type A?
MoCD Type A is a devastating condition caused by a defective MOCS1 gene that stops the body from producing cyclic pyranopterin monophosphate (cPMP). Without cPMP, toxic sulphites build up, leading to brain damage, seizures, and feeding problems in infants.
MHRA Backs Fosdenopterin After Rigorous Checks
- The MHRA approved fosdenopterin for use across Great Britain, utilising the European Commission’s Decision Reliance Procedure.
- This followed advice from the Committee for Medicinal Products for Human Use (CHMP), ensuring top regulatory standards were met.
- Patient safety is paramount; stringent measures and ongoing monitoring will guarantee the drug’s safe use.
- Fosdenopterin is given intravenously as a 9.5 mg powder dissolved for injection via catheter.
Hope for Families and Future Monitoring
Fosdenopterin offers new hope to babies and families battling this rare genetic disorder. Although approval marks a huge medical step, constant vigilance remains essential to keep patients safe.
